RxDoctor Payments Data

Chi-Whei Lin, MD

Internal Medicine · Laguna Hills, CANPI 1114057254

Payments from drug & device makers

$2,328in general payments, 2019–2025

Across 119 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$415
  • Revance Therapeutics, Inc.$384
  • GSK$284
  • Johnson & Johnson$278
  • Boehringer Ingelheim$275
  • AstraZeneca$193
  • plus $497 from 13 others

What the payments were for

  • Food & beverage$2,319100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,328 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$59,316
Medicare patients
192
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate68$98,038
EliquisApixaban50$69,343
OzempicSemaglutide53$48,904
JardianceEmpagliflozin23$38,469
XareltoRivaroxaban31$38,290
ProliaDenosumab17$26,576
MyrbetriqMirabegron31$21,610
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,583
Metoprolol Succinate253$4,487
Atorvastatin Calcium429$4,210
Losartan Potassium363$3,699
Omeprazole237$2,948
Levothyroxine Sodium222$2,860
Tamsulosin Hcl142$2,580
Amlodipine Besylate404$2,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$47$98,03868 claims
PfizerEliquis, Paxlovid$87$70,658102 claims
Novo NordiskOzempic$24$48,90453 claims
Boehringer IngelheimJardiance$275$38,46923 claims
Johnson & JohnsonXarelto$278$38,29031 claims
AmgenProlia$18$26,57617 claims
Astellas Pharma US IncMyrbetriq$415$21,61031 claims
GSKTrelegy Ellipta$284$13,58315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →